CSL Limited Annual Report 2021/22 12 Our Product Portfolio CSL Behring We meet patients’ needs using the latest recombinant and plasma-derived technologies. CSL Behring discovers, develops and delivers the broadest range of products in the industry for treating rare and serious diseases such as haemophilia, von Willebrand disease (vWD), primary immune deficiencies (PID), chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary angioedema (HAE) and inherited respiratory disease. CSL Behring’s products are also used in cardiac surgery, for burns treatment and for urgent warfarin reversal. Immunology Our world leading immunoglobulin franchise is the cornerstone of the immunology therapeutic area. Key CSL Behring products in market include PRIVIGEN®, HIZENTRA®, BERINERT®, HAEGARDA® and a range of hyperimmunes. Haematology We are focused on maximising the value of our existing portfolio, developing new therapies and identifying transformational treatments to help patients realise a life full of potential. Key CSL Behring products in market include IDELVION®, AFSTYLA®, HUMATE P®/HAEMATE®, BERIPLEX®/KCENTRA®, VONCENTO®/BIOSTATE® and albumin. Cardiovascular and metabolic We are focused on improving and extending the lives of patients with cardiovascular disease (CVD) and diabetic kidney disease. Respiratory Respiratory diseases impose an enormous burden on patients and society and are a leading cause of death and disability worldwide. Key CSL Behring products in market include ZEMAIRA®/RESPREEZA®. Transplant While advances in transplantation techniques and therapies have markedly improved short-term patient survival, transplant rejection remains one of the greatest limitations to long-term graft and patient survival for both solid organ and haematopoietic stem cell transplant recipients. We are focused on developing therapies to address transplant rejection. CSL Seqirus Our broad range of influenza vaccines meets the needs of different populations around the world. In Australia and New Zealand, CSL Seqirus is a leading provider of in-licensed vaccines and specialty pharmaceuticals. It is also the world’s only supplier of a unique range of products made in the national interest for the Australian Government, including antivenoms and Q fever vaccine. Influenza Vaccines Egg-based and cell-based products, seasonal, pre-pandemic and pandemic influenza vaccines. Products of National Significance Q fever vaccine and antivenoms for venomous creatures in Australia and other Pacific countries. In-licensed Vaccines and Pharmaceuticals For Australia and New Zealand. 2 Our Company
RkJQdWJsaXNoZXIy MjE2NDg3